Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 74.29% is 472% above its 4-year average of -19.98%, near the high end of its 4-year range (-509.21%–100.00%).
214.96% above its 12-month average of 23.59%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 100.00%.
GROSS MARGIN
74.29%
GROSS MARGIN AVG TTM
23.59%
GROSS MARGIN AVG 3Y
-6.72%
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+214.96%
CURRENT VS 3Y AVG
+1206.17%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.82%
median of 781 covered companies
CURRENT VS SECTOR MEDIAN
+81.99%
vs the sector median at left
Metagenomi, Inc. Common Stock
Market Cap
$40.09M
Gross Margin
74.29%
TTM Avg
23.59%
3Y Avg
-6.72%
5Y Avg
N/A
Market Cap
$40.22M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$38.61M
Gross Margin
58.16%
TTM Avg
55.59%
3Y Avg
55.93%
5Y Avg
56.24%
Market Cap
$37.93M
Gross Margin
0.00%
TTM Avg
-93.03%
3Y Avg
-21.51%
5Y Avg
10.85%
Market Cap
$37.18M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
22.09%
Market Cap
$43.51M
Gross Margin
75.20%
TTM Avg
76.17%
3Y Avg
74.22%
5Y Avg
71.65%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $40.09M | 74.29% | 23.59% | -6.72% | N/A |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.22M | 0.00% | 0.00% | 0.00% | 0.00% |
| Nephros, Inc. (NEPH)vs › | $39.84M | 60.31% | 61.36% | 57.30% | 56.95% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.61M | 58.16% | 55.59% | 55.93% | 56.24% |
| Precipio, Inc. (PRPO)vs › | $41.92M | 43.69% | 45.94% | 39.54% | 34.01% |
| Incannex Healthcare Limited (IXHL)vs › | $37.93M | 0.00% | -93.03% | -21.51% | 10.85% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.60M | 0.00% | 0.00% | 0.00% | 15.78% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $37.18M | 0.00% | 0.00% | 0.00% | 22.09% |
| SANUWAVE Health Inc. (SNWV)vs › | $43.51M | 75.20% | 76.17% | 74.22% | 71.65% |
| Nano-X Imaging Ltd. (NNOX)vs › | $43.78M | -98.21% | -96.12% | -84.75% | -75.83% |
Gross Margin
74.3%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 100.00% |
| 2026-03-31 | 30.85% |
| 2025-12-31 | 66.76% |
| 2025-09-30 | 84.71% |
| 2025-06-30 | -164.38% |
| 2025-03-31 | -509.21% |
| 2024-12-31 | 100.00% |
| 2024-09-30 | 100.00% |
| 2024-06-30 | 100.00% |
| 2024-03-31 | -181.74% |
| 2023-12-31 | -99.65% |
| 2023-09-30 | -117.08% |
| 2023-06-30 | -100.06% |
| 2023-03-31 | -132.53% |
| 2022-12-31 | 87.15% |
| 2022-09-30 | 89.99% |
| 2022-06-30 | -151.87% |
| 2022-03-31 | -151.87% |
